By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.




Key Statistics


Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics
Employees: 429
Symbol: NKTR
 









Company News
Nektar Therapeutics (NKTR) Publishes Pre-Clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research 2/1/2016 7:26:01 AM
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA 1/7/2016 10:40:49 AM
Nektar Therapeutics (NKTR) To Present At Oppenheimer 26th Annual Healthcare Conference In New York 12/9/2015 6:30:27 AM
Nektar Therapeutics (NKTR) Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine 12/8/2015 9:41:32 AM
Nektar Therapeutics (NKTR) To Present At Jefferies Autumn 2015 Global Healthcare Conference In London 11/17/2015 9:58:24 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The Third Quarter Of 2015 11/6/2015 7:33:04 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Third Quarter 2015 On Thursday, November 5, 2015, After Close Of U.S.-Based Financial Markets 10/30/2015 6:44:57 AM
Nektar Therapeutics (NKTR) Chief Science Officer Provides Details on Immuno-Oncology, Pain Pipelines 10/9/2015 1:34:21 PM
Nektar Therapeutics (NKTR) Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day 10/9/2015 12:56:30 PM
Nektar Therapeutics (NKTR) Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies 10/7/2015 6:55:58 AM
12345678910...
//-->